Reaction
Leukoderma reporting signals
As of the last recalculation, Leukoderma appears in 197 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is NIVOLUMAB (PRR 234.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nivolumab | 103 | 234.8 | 235.1 |
| Ipilimumab | 44 | 138.4 | 138.5 |
| Dabrafenib | 8 | 41.8 | 41.8 |
| Trametinib | 8 | 36.4 | 36.4 |
| Encorafenib | 3 | 32.5 | 32.5 |